Phase Thank us the presentation our program recently And MS announced with beginning. Sean, is morning. Jenna, study and well for and the you, of of to of the thank you inhibitor thank The Hengrui. updated actions a I in-licensing Phase just umbralisib BTK this all in you, II the novel data and Oncology Jiangsu the our study off Lancet of is from XXXX this as great start from joining as of publication
expect We developments throughout to many XXXX. exciting report
received ublituximab lymphocytic raised GENUINE the like XXXX. ASCO the antibody of We announced of of into the an our development Phase in our to with the conferences publication Phase trial quarter. with additional We review II for the Before finally, positive UNITY-CLL launched drug January combination into combination this major fourth in PD-LX the and from trials quarter. leaving chronologically. by evaluating I've in $XX of million raised various Meeting trial well of $XXX in from Annual diffuse off we of from listed course recapping highlights We in-store ULTIMATE with ublituximab data an We the we million a in B-cell. We an Haematology. with the forma and monoclonal million large in X approximately a leukemia for for trial MS. enrollment in chronic And the MS them designation pro clinical of the year, ublituximab ublituximab for June. of in of at the presented a total being year. patients what's Phase presented orphan exciting thus positive us cash and XXXX advanced III $XXX at with kick sheet the data healthy the Journal trial cash on and to over And far Phase year III throughout British completed XXXX, of balance third treatment some the this XXXX the come. I/II remainder in Phase We ibrutinib call umbralisib the III I'd
the I'll review III begin current now the and ongoing of UNITY-CLL. Let's Phase our status pivotal with programs.
study As refractory FDA of III as of study with in a umbralisib active ublituximab brief or is relapsed and UX, lymphocytic and trial a compared ublituximab or trial Phase refer reminder, large randomized combination being patients. both is with patients plus an a to control This the we in the UNITY-CLL to treatment-naïve is including Special over chlorambucil XXX global with under chronic conducted leukemia. Assessment the combination, Protocol
the the relapsed ahead study for of the And schedule. XX% patients frontline, October, were of exceeded enrolled completed or XX% we demand expectations. last approximately nearly months were and enrollment refractory. our this nine announced Approximately As
quarter response the XXXX. of expect topline study to overall We this be in results available second in
improvement seek we remind overall in Let everyone XX% the a that to in plan if file approval of for targeting are me absolute And fourth XXXX. response. successful, to quarter we accelerated
me very support Following primary the a a approval give full the combination overall the CLL. survival ideally update. let of is readout, response progression-free GENUINE and the this of for study broad for endpoint treatment to that, quick support With label
III RITUXAN. MURANO accelerated light with the need venetoclax in with of we As data results accelerated study regards a to which from plus the presented the We to Recall, rate compared the the as to results randomized CLL. In is with compare reminder, MURANO of for with showed ublituximab therapies, will trial ibrutinib the which results, rate GENUINE trial guidance last a The file from FDA by these to which GENUINE at given a plus response response overall approval, include ibrutinib eager review. CR high-risk to XX% rate available XX% overall believe quite complete in all XXXX results we that to Phase we year an order a see ASH monotherapy at year, our XX% to an our study RITUXAN patients by approval, of venetoclax plus independent showed as will nicely last were response confirmed time. August of X% believe compare rate. were
and median and of we portion population, were were including rates as challenging high we believe risk that of similar a avoidance may is opposed this believe mind, three of MURANO, a which with therapy. information venetoclax prior all one MURANO, high-risk with median being patients all BLA strong available RITUXAN, we are include we these may life-threatening example, benefit benefit fatal we that over GENUINE provide show submission therapy. have the story venetoclax, over associated the of with meaningful nicely for we in and the With included a lysis While show between tumor patient prior more meaningful Again, coming believe including, would we response GENUINE, that of syndrome arguments a treating in GENUINE of we together line to potential patients pieces therapy therapy. in only and/or lines believe to think a
decision, filing are continuing quarter BLA While drive in of we to with third made the have this final preparation file to the we goal of ready being year. a not the the of
the Now turn to I'd UNITY-NHL like to our trial. discussion
subtypes lymphoma, large including the recall, three marginal lymphoma. UNITY-NHL you and As has may non-Hodgkin's lymphoma; three parts follicular of B-cell independent targeting lymphoma; trial diffuse zone
the the approximately single cohort, follicular in the we arm targeting a a accelerated this of copanlisib. umbralisib And are XXX we this of into cohort. similar monotherapy population patients, number patient of approval currently with start in Let's In are supported enrolling same that cohort.
We mid-XXXX. in complete enrollment expect to achieve
relapsed into zone to cohort, cohort. we're let's monotherapy currently follicular lymphoma. marginal zone the review enrolling the refractory Similar a with for Next, marginal arm single patients of umbralisib or also
patients, following based XX% rate. in overall a which ibrutinib approval, the response is showed Here, a arm on trial we're single XX and
enrollment is this cohort into this the of goal fourth to year. in Our complete quarter
the cohort. review B-cell large diffuse let's Lastly,
UX have trial. or of currently enrolling plus We into patients are single ublituximab this And arm arm now to or bendamustine. B-cell the a plus we completed a large of UX umbralisib refractory diffuse with enrollment relapsed
We the all data to enrollment program. plus gears topline in cohorts MS key into our the are of if available and switch UX be XXXX. should the goes benda by half that, from mid-year. three for we highlights of cohort study as let's all some targeting With planned, discuss UNITY-NHL complete have able Accordingly, first
pleased are and in trials to report Assessment called evaluating Protocol that Special trials me we I and open relapsing two Let enrollment am everyone ublituximab MS. running forms Europe. and ULTIMATE of for underway under II, Phase the in III well that remind U.S. both I are identical ULTIMATE the
its Phase II ublituximab clinical and complete we targeting for in approved think we a opportunity to in are $X two the approximately last enrollments is ublituximab, Meeting to quarter III an Phase XXX shareholders. Ocrelizumab, We data at the program, was major with XXXX. trial the patients billion in of first first our the of represents anti-CDXX generate studies MS year. our presented recently monoclonal MS across and updated antibody in Supporting ACTRIMS us like Annual month. about sales Accordingly, MS for tracking slated from
relapse-free of which With Phase we now study these operator XX data year, so the it very presented weeks are pleased remarks. And some begin have to of which, XX XX the patients and call nicely, enrolled over all this presenting II XX Q&A ocrelizumab following of concluding the patients trial through treatment. that, from III II the confirmed the I'd XX.X% to patients session, one-year turn conference report on return from to presented full to and will treatment. Phase treated forward I weeks was will look like data later were of studies. both provide the in include This and compares the to through data that after We
